Keryx sags after withdrawing guidance

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) fell $1.08 (17%) to $5.15 Tuesday after it reported 3Q17 earnings and withdrew its 2017 guidance. The company reported revenues of $15 million for the quarter, falling short of the $18 million consensus estimate.

Keryx said sales of its only product, Auryxia ferric citrate, were lower than expected due to payer dynamics and slower growth in prescriptions than expected. In July, Keryx had raised full-year Auryxia sales guidance to $62-$66 million from $56-$60 million...